Storia in 3 fonti

EU and US advisers split over AstraZeneca breast cancer drug

Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout

Raccontata da

statnews.com

endpoints.news

fiercepharma.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo1 mesi fa

EU and US advisers split over AstraZeneca breast cancer drug

Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout

originale

fiercepharma.com1 mesi fa

Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust…

Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. | Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with reports of three positive…

Leggi questa versione → originale

Timeline cronologica

giovedì 21 maggio 2026·statnews.com
Immunovant shares surge on arthritis trial data
Trial results for Lilly's "triple-G" drug, FDA's leadership purge leaves chaos, and more biotech news from The Readout
giovedì 21 maggio 2026·endpoints.news
Merck partner Kelun outlines Phase 3 lung cancer success in China study
Merck partner Kelun-Biotech fleshed out a Phase 3 win in lung cancer from a study in China for the experimental antibody-drug conjugate sac-TMT, raising hopes that the benefit…

EU and US advisers split over AstraZeneca breast cancer drug

Confronto fonti

EU and US advisers split over AstraZeneca breast cancer drug

Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust…

Timeline cronologica

Immunovant shares surge on arthritis trial data

Merck partner Kelun outlines Phase 3 lung cancer success in China study

EU and US advisers split over AstraZeneca breast cancer drug

Confronto fonti

EU and US advisers split over AstraZeneca breast cancer drug

Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust…

Timeline cronologica

Immunovant shares surge on arthritis trial data

Merck partner Kelun outlines Phase 3 lung cancer success in China study

Merck partner Kelun outlines Phase 3 lung cancer success in China study

Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss

EU and US advisers split over AstraZeneca breast cancer drug

Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm

AstraZeneca wins EU backing for breast cancer drug, splitting with FDA panel